NCT01515800已完成不适用
S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 724
- 试验地点
- 204
- 主要终点
- Time to first evidence of adherence failure (discontinuation)
研究概览
简要总结
RATIONALE: Measuring how text-message affects treatment compliance in women with breast cancer may help doctors plan the best treatment.
PURPOSE: This randomized trial studies how well text-message works in reducing early discontinuation of aromatase inhibitor therapy in patients with early-stage breast cancer who underwent breast surgery.
详细描述
OBJECTIVES:
Primary
- To determine the efficacy of a reminder message, sent by text message to mobile phones twice weekly, to improve adherence to adjuvant aromatase inhibitor (AI) therapy as determined by urinary AI levels in women with early-stage hormone-sensitive breast cancer versus usual care.
Secondary
- To compare the effect of a reminder message sent twice weekly to mobile phones as compared to usual care to improve adherence to adjuvant AI therapy according to self-report.
- To explore the efficacy of the text message intervention for reducing early discontinuation as compared to usual care at 12, 24, and 36 months of adjuvant AI therapy in subgroups of breast cancer patients as defined by age group, stage, year of therapy, education, race/ethnicity, teaching hospital versus community hospital, AI-related side effects (as determined by serial questionnaires), insurance status, and prescription co-pay status.
- To explore the reasons for early discontinuation of AI therapy in those who do discontinue in the intervention and control group by querying quality of life as assessed by the Functional Assessment of Cancer Therapy-Endocrine Subscales (FACT-ES) and symptoms and other issues related to hormonal therapy at each follow-up visit, using the Brief Pain Inventory (BPI-SF), and at annual visits the Beliefs about Medicine Questionnaire (BQM) and the Treatment Satisfaction Questionnaire for Medication (TSQM).
- To conduct a sensitivity analysis assessing time to last evidence of adherence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Patients must be women with a diagnosis of histologically confirmed, primary invasive, hormone-sensitive (estrogen receptor-positive [ER]/progesterone receptor [PR]-positive) adenocarcinoma of the breast (Stage I, II or III) with no evidence of recurrent or metastatic disease (M0)
- •Patients must have a mobile phone that can receive text messages and must currently use or be willing to learn to use text messaging
- •PATIENT CHARACTERISTICS:
- •Patients must be postmenopausal, as defined by at least one of the following:
- •≥ 12 months since the last menstrual period
- •Prior bilateral oophorectomy
- •Previous hysterectomy with one or both ovaries left in place (or previous hysterectomy in which documentation of bilateral oophorectomy is unavailable) AND follicle-stimulating hormone (FSH) values consistent with the institutional normal values for the postmenopausal state; FSH levels must be obtained within 28 days prior to registration
- •Patients must be willing to provide urine specimen to test for the presence of aromatase inhibitor within 28 days of randomization and at each 3-month clinic visit for 3 years
- •Patients must have the ability to speak and read English
- •Patients must have a Zubrod performance status of 0 - 2
- •No other prior malignancy (i.e., other than as noted on disease characteristics) is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for > 5 years
- •Patients are allowed to participate in another clinical trial as long as it does not interfere with daily intake of aromatase-inhibitor therapy
- •PRIOR CONCURRENT THERAPY:
- •Patients must be post adjuvant chemotherapy (if to be utilized) and primary curative surgery and must have recovered from all side-effects of the surgery
- •Trastuzumab (Herceptin) given alone after cytotoxic chemotherapy is considered adjuvant chemotherapy; patients would be eligible upon completion of Herceptin as long as the other eligibility criteria are met
- •Patients must be currently taking an aromatase inhibitor (AI), have completed at least one month of AI therapy, be within the first 5 years of planned AI therapy, and have at least 3 years remaining before completion of planned AI therapy
排除标准
- •Insufficient evidence of post-menopausal status; metastatic or recurrent disease; currently receiving chemotherapy.
研究组 & 干预措施
No text message reminder
No Intervention
Patients receive standard follow-up care.
Text message reminder
Experimental
Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
干预措施: Text message reminder (Behavioral)
结局指标
主要结局
Time to first evidence of adherence failure (discontinuation)
时间窗: Every 3 months after randomization
次要结局
- Adherence effect of text message compared to usual care using the patient self-report responses to AI Usage form(Every 3 months after randomization)
- Relationship between randomized arm and various participant, site and health insurance characteristics(Every 3 months after randomization)
- Reasons for early discontinuation of AI therapy among intervention arm and control arm as assessed by quality-of-life questionnaires(Every 3 months after randomization)
- Time to last evidence of adherence(Every 3 months after randomization)
研究者
研究点 (204)
Loading locations...
相似试验
尚未招募
Unknown
Text Messaging in first episode psychosisCTRI/2024/04/065474JIPMER
Unknown
不适用
Effect of SMS reminders on treatment retention rates among patients with first episode psychosisCTRI/2021/03/031679JIPMER30
Unknown
不适用
Text Message (SMS) to Help Cancer Patients in Chemotherapy TreatmentSide EffectCancerNCT03087422Samanta Winck Madruga80
已完成
不适用
Text Messaging Adherence to Stimulant MedicationAttention Deficit Hyperactivity DisorderNCT01967485Massachusetts General Hospital35
尚未招募
不适用
Clinical Application of Text Messaging for Anxiety and DepressioMental Health - AnxietyMental Health - DepressionAnxietyDepressionACTRN12621000410853Australian Catholic University450